Cargando…

Development of a Single Vial Kit Solution for Radiolabeling of (68)Ga-DKFZ-PSMA-11 and Its Performance in Prostate Cancer Patients

Prostate-specific membrane antigen (PSMA), a type II glycoprotein, is highly expressed in almost all prostate cancers. By playing such a universal role in the disease, PSMA provides a target for diagnostic imaging of prostate cancer using positron emission tomography/computed tomography (PET/CT). Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ebenhan, Thomas, Vorster, Mariza, Marjanovic-Painter, Biljana, Wagener, Judith, Suthiram, Janine, Modiselle, Moshe, Mokaleng, Brenda, Zeevaart, Jan Rijn, Sathekge, Mike
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332425/ https://www.ncbi.nlm.nih.gov/pubmed/26287143 http://dx.doi.org/10.3390/molecules200814860

Ejemplares similares

Towards Facile Radiolabeling and Preparation of Gallium-68-/Bismuth-213-DOTA-[Thi(8), Met(O(2))(11)]-Substance P for Future Clinical Application: First Experiences
por: Suthiram, Janine, et al.
Publicado: (2021)

(68)Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients
por: Sathekge, Mike, et al.
Publicado: (2016)

(68)Ga-PSMA-11 PET/CT in primary staging of prostate carcinoma: preliminary results on differences between black and white South-Africans
por: Sathekge, Mike, et al.
Publicado: (2017)

Synthesis, (68)Ga-Radiolabeling, and Preliminary In Vivo Assessment of a Depsipeptide-Derived Compound as a Potential PET/CT Infection Imaging Agent
por: Mokaleng, Botshelo B., et al.
Publicado: (2015)

(213)Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
por: Sathekge, Mike, et al.
Publicado: (2017)

Preclinical Assessment of a (68)Ga-DOTA-Functionalized Depsipeptide as a Radiodiagnostic Infection Imaging Agent
por: Ebenhan, Thomas, et al.
Publicado: (2017)

Preclinical Assessment Addressing Intravenous Administration of a [(68)Ga]Ga-PSMA-617 Microemulsion: Acute In Vivo Toxicity, Tolerability, PET Imaging, and Biodistribution
por: Mandiwana, Vusani, et al.
Publicado: (2021)

Tachykinin Receptor-Selectivity of the Potential Glioblastoma-Targeted Therapy, DOTA-[Thi(8),Met(O(2))(11)]-Substance P
por: Suthiram, Janine, et al.
Publicado: (2023)

PSMA Theranostics: Science and Practice
por: Mokoala, Kgomotso, et al.
Publicado: (2021)

Global experience with PSMA-based alpha therapy in prostate cancer
por: Sathekge, Mike M., et al.
Publicado: (2021)

Antimicrobial Peptides: Their Role as Infection-Selective Tracers for Molecular Imaging
por: Ebenhan, Thomas, et al.
Publicado: (2014)

Radiolabeled PSMA Inhibitors
por: Neels, Oliver C., et al.
Publicado: (2021)

First Results and Experience with PRRT in South Africa
por: Vorster, Mariza, et al.
Publicado: (2018)

Current Status of (68)Ga-Pentixafor in Solid Tumours
por: Hadebe, Bawinile, et al.
Publicado: (2022)

Tetraethylammonium tricarbonylchlorido(quinoxaline-2-carboxylato-κ(2) N (1),O)rhenate(I)
por: Suthiram, Janine, et al.
Publicado: (2010)

(68)Ga‐nitroimidazole PET/CT imaging of hypoxia in tuberculosis: A case series
por: Bresser, Philippa L, et al.
Publicado: (2022)

Therapeutic response and side effects of repeated radioligand therapy with (177)Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2016)

(68)Ga-PSMA-11 PET/CT Initial Staging in Black and White South African Males with ISUP Grade Group 1 and 2 Prostate Adenocarcinoma
por: Maserumule, Letjie C., et al.
Publicado: (2022)

Tetraethylammonium tricarbonylchlorido(pyrazine-2-carboxylato-N (1),O)rhenate(I)
por: Suthiram, Janine, et al.
Publicado: (2009)

PSMA as a target for radiolabelled small molecules
por: Eder, Matthias, et al.
Publicado: (2013)

Preparation of (177)Lu-PSMA-617 in Hospital Radiopharmacy: Convenient Formulation of a Clinical Dose Using a Single-Vial Freeze-Dried PSMA-617 Kit Developed In-House
por: Guleria, Mohini, et al.
Publicado: (2021)

(225)Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
por: Sathekge, Mike, et al.
Publicado: (2018)

Comparison of Accuracy in Calculation of Absorbed Dose to the Kidneys Following Radioligand Therapy with (177)Lu-DKFZ-PSMA-617 by Two Different Background Correction Methods
por: Mahmoudi, Elahe, et al.
Publicado: (2022)

Erythromycin as an alternative to reduce interfering extra-cardiac activity in myocardial perfusion imaging
por: Vorster, Mariza, et al.
Publicado: (2010)

Renal osteodystrophy presenting as a metabolic superscan on F-18 FDG PET/CT: A case report
por: Lawal, Ismaheel, et al.
Publicado: (2017)

Comparison of the radiolabeled PSMA-inhibitor (111)In-PSMA-617 and the radiolabeled GRP-R antagonist (111)In-RM2 in primary prostate cancer samples
por: Schollhammer, Romain, et al.
Publicado: (2019)

Dual Radiolabeling as a Technique to Track Nanocarriers: The Case of Gold Nanoparticles
por: Rambanapasi, Clinton, et al.
Publicado: (2015)

Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach
por: Kgatle, Mankgopo M., et al.
Publicado: (2021)

Multi-curie production of gallium-68 on a biomedical cyclotron and automated radiolabelling of PSMA-11 and DOTATATE
por: Thisgaard, Helge, et al.
Publicado: (2021)

A toxicity profile of the Pheroid® technology in rodents
por: Kleynhans, Janke, et al.
Publicado: (2019)

Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2015)

ProtSweep, 2Dsweep and DomainSweep: protein analysis suite at DKFZ
por: del Val, C., et al.
Publicado: (2007)

The Added Value of a Single-photon Emission Computed Tomography-Computed Tomography in Sentinel Lymph Node Mapping in Patients with Breast Cancer and Malignant Melanoma
por: Bennie, George, et al.
Publicado: (2015)

Burkitt lymphoma and cavernous sinus syndrome with breast uptake on (18)F-FDG-PET/CT: A case report
por: Reyneke, Florette, et al.
Publicado: (2017)

The Radiolabeling of [161Tb]-PSMA-617 by a Novel Radiolabeling Method and Preclinical Evaluation by In Vitro/In Vivo Methods
por: UYGUR, EMRE, et al.
Publicado: (2023)

Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy
por: Abusalem, Mohammed, et al.
Publicado: (2023)

Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?
por: Felber, Veronika Barbara, et al.
Publicado: (2021)

(225)Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings
por: Sathekge, Mike, et al.
Publicado: (2023)

(68)Ga, (44)Sc and (177)Lu-labeled AAZTA(5)-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
por: Sinnes, Jean-Philippe, et al.
Publicado: (2020)

The SARS-COV-2 Seroprevalence among Oncology Patients
por: Kgatle, Mankgopo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_85t7dgq1tql1l3bq8llqnmqadt